<< Read Full Article
<< Read Full Article
CHANGE IN RATINGS
DR Horton (DHI Quote) downgraded at Credit Suisse to Underperform. $7.50 price target. Stock is trading at a premium valuation in a tough selling climate.Energizer (ENR Quote) upgraded at UBS from Sell to Neutral. Valuation call, as the stock is down 28% year-to-date. $40 price target.
Genzyme (GENZ Quote) downgraded at Citigroup from Buy to Hold. $61 price target. No visibility on Lumizyme approval, following the new 6-month delay. Estimates also lowered.
Noble (NE Quote) upgraded at Goldman Sachs to Buy from Neutral based on valuation. Shares are trading at 19% discount to peers based on EBITDA. Note that company is in strong position to make acquisitions during downcycle. Price target raised to $32 from $30. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.68 | 1,109.24 | 2,185.03 | 33.23 |
Oil *
77.73
|
|
DOWN
18.90
|
UP
0.38
|
UP
9.22
|
UP
0.48
|
10 Yr
3.32%
SPDR Gold
119.18
|
|
-0.18%
|
+0.03%
|
+0.42%
|
+1.47%
|
Data delayed 20 minutes |


Connect with TheStreet